Defense Production Act & Buy American for Medical Devices (2026)
A decision guide for medical device makers on U.S. domestic incentives: DPA Title III grants, Buy American Act thresholds, TAA exemptions, and tax rules.
Executive Summary
Driven by post-pandemic supply chain vulnerabilities, escalating geopolitical tensions, and aggressive domestic industrial policies, medical device manufacturers face unprecedented financial incentives and statutory mandates to establish onshore production in the United States. Navigating the complex landscape of federal manufacturing incentives requires understanding how distinct statutes interact, which mechanisms apply to specific device categories, and how to execute the financial trade-offs of domestic reshoring.
Key elements of the federal medical device manufacturing incentive framework include:
- Defense Production Act Title III (50 U.S.C. §§ 4531–4534): Administered primarily through the Department of Defense (DoD) Industrial Base Policy, Title III provides direct capital grants, loans, and purchase commitments to expand domestic industrial capacity for critical medical supplies, components, and active equipment.
- Buy American Act (BAA) Threshold Evolution: Governed by FAR Subpart 25.1, the domestic content requirement for federal procurement of non-commercial end items stands at 65% for calendar years 2024 through 2028, and is scheduled to rise to 75% in 2029. Offers containing foreign end items incur a 20% price evaluation penalty (30% for small-business set-asides).
- The Trade Agreements Act (TAA) Exemption: Under 19 U.S.C. § 2501, medical devices manufactured in TAA-designated countries (such as the EU, Japan, Mexico, and South Korea) are exempt from BAA restrictions for covered federal procurements, explaining why many foreign-assembled devices qualify for Department of Veterans Affairs (VA) and DoD contracts.
- Executive Order 13944 vs. 2025 Pharma Orders: While 2025 Executive Orders focused heavily on active pharmaceutical ingredients (APIs), medical devices remain anchored to Executive Order 13944, which designated 96 medical device product codes (including ventilators, personal protective equipment, and diagnostic testing kits) as essential medical countermeasures subject to federal procurement preferences.
- 2025–2026 Tax & Regulatory Incentives: The One Big Beautiful Bill Act (OBBBA, P.L. 119-21, signed July 4, 2025) introduced Section 168(n) Qualified Production Property, allowing 100% immediate expensing of domestic manufacturing facilities, restored 100% bonus depreciation on production equipment under Section 168(k), and added Section 174A domestic research and experimental (R&E) expensing.
Scenario & Direct Answer
Manufacturer Scenario: Our medical device company currently manufactures diagnostic disposables and surgical instruments in Southeast Asia. We are evaluating whether to build a greenfield manufacturing plant in North Carolina. Which federal grants, tax credits, and procurement preferences apply to our device category in 2026, and how do we compute the net ROI?
Direct Answer: If you transition manufacturing to the United States, three main federal policy levers apply to your medical device business:
- Procurement Preferences & Protections: Under the Buy American Act (FAR Part 25), domestic manufacture grants your devices a 20% to 30% price evaluation advantage in VA and DoD procurements. Furthermore, if Commerce completes its ongoing Section 232 investigation into imported medical supplies, foreign-made disposables will face substantial tariffs, making onshore production essential to preserve U.S. hospital market share.
- Capital Grants & Contracts: Via the Defense Production Act Title III Industrial Base Analysis and Sustainment (IBAS) program, qualified device makers can apply for non-dilutive capital grants and long-term supply agreements from DoD, BARDA, and the Strategic National Stockpile (SNS).
- Tax & Expensing Rules: Under OBBBA Section 168(n) and Section 174A, 100% of your U.S. manufacturing facility equipment and domestic R&D expenses can be immediately written off in Year 1, offsetting domestic labor cost premiums.
Devices manufactured in Trade Agreements Act (TAA) designated partner nations remain eligible for U.S. federal contracts, but items produced in non-TAA countries (such as China) face disqualification or severe price penalties.
Defense Production Act Authorities: Titles I, III, and VII
The Defense Production Act (DPA) of 1950 (50 U.S.C. § 4501 et seq.) provides three primary operational titles that impact medical device manufacturers during national defense actions and public health emergencies.
DPA Title I: Priorities and Allocations (50 U.S.C. §§ 4511–4519)
Under Title I, the President (delegated to HHS under Executive Order 13603) can mandate that domestic medical device suppliers prioritize federal government orders over commercial contracts:
- DO/DX Rating System: Orders assigned a DX rating (highest national defense priority) or DO rating (critical operational priority) must be filled before unrated commercial orders, regardless of pre-existing commercial delivery schedules.
- Health Resources Priority and Allocations System (HRPAS): Governed by 45 CFR Part 101, HRPAS permits HHS to allocate raw materials (such as medical-grade polymers, titanium, or microchips) directly to designated medical device manufacturers during critical shortages.
DPA Title III: Expansion of Productive Capacity (50 U.S.C. §§ 4531–4534)
Title III is the financial engine of the DPA, authorizing federal capital disbursements to establish, expand, or preserve domestic manufacturing lines.
- 50 U.S.C. § 4531 (Declaration of Policy): Establishes that domestic industrial capacity for critical medical countermeasures and health resources is essential to national security.
- 50 U.S.C. § 4532 (Loans and Loan Guarantees): Authorizes the federal government to issue direct loans or guarantee private loans to domestic manufacturers to expand production capacity, acquire specialized tooling, or modernize facilities.
- 50 U.S.C. § 4533 (Purchase Commitments and Capital Assistance): Authorizes the government to issue direct capital grants, enter into long-term purchase commitments (offtake agreements), and install government-owned equipment in private manufacturing plants.
- 50 U.S.C. § 4534 (Defense Production Act Fund): Establishes the dedicated treasury fund for Title III disbursements, managed by the Office of the Assistant Secretary of Defense for Industrial Base Policy (OASD[IBP]) through the Defense Production Act Title III Program Office, in coordination with HHS.
DPA Title VII: General Provisions & Voluntary Agreements (50 U.S.C. §§ 4551–4568)
Title VII authorizes antitrust immunity for domestic device manufacturers who participate in voluntary agreements under federal coordination to share supply-chain data, standardize component specifications, or coordinate distribution during national health emergencies.
Historic Medical Device & Countermeasure DPA Awards
During national health emergencies, Title III grants transformed U.S. domestic medical device manufacturing capacity. Major baseline awards include:
| Recipient / Sponsor | Award Amount | Target Device / Technology | Procurement Mechanism |
|---|---|---|---|
| Phlow Corporation | $354M (Base) / $812M (Total) | Continuous manufacturing for essential medicines & diagnostic reagents | DPA Title III / BARDA Contract |
| Corning Incorporated | $204M | Valor® Glass vials and specialized diagnostic glass tubing | DPA Title III Capital Grant |
| SiO2 Materials Science | $143M | Engineered polymer-glass primary packaging for biologicals & IVDs | DPA Title III Facility Expansion |
| ApiJect Systems | $138M | High-speed Blow-Fill-Seal (BFS) prefilled syringe manufacturing | DPA Title III Capacity Expansion |
| Retractable Technologies | $27.3M | Automated safety syringe and needle manufacturing lines | DPA Title III Direct Procurement |
To analyze how domestic facility capacity compares across regions, see our study on FDA Device Establishment Registration & Global Manufacturing Footprints.
Strategic National Stockpile (SNS) & BARDA Procurement Frameworks
In addition to DPA Title III grants, medical device manufacturers seeking domestic revenue stability rely on multi-year procurement programs managed by the Strategic National Stockpile (SNS) and the Biomedical Advanced Research and Development Authority (BARDA).
Strategic National Stockpile (SNS) Models
The SNS maintains a multibillion-dollar repository of critical medical equipment, PPE, and diagnostics to respond to public health emergencies:
- Vendor-Managed Inventory (VMI): Rather than storing devices in federal warehouses where products risk expiration, the SNS enters into VMI contracts with domestic device makers. Under VMI, manufacturers hold fresh product inventory in their own distribution channels while guaranteeing emergency access to the federal government within 24 to 48 hours.
- Warm-Base Manufacturing Agreements: The federal government pays domestic device companies annual baseline fees to maintain "warm" assembly lines that can scale from commercial volumes to 10x capacity within 30 days of activation.
BARDA Drive & Medical Countermeasure Funding
BARDA provides non-dilutive contract funding for advanced development of novel diagnostic platforms, rapid pathogen testing hardware, and portable ventilators through its BARDA Drive incubator and Division of Research, Development, and Innovation (RDI).
State-Level Manufacturing Incentives & Tax Stacking Strategy
In addition to federal programs, state economic development agencies offer aggressive subsidies for medical device plant construction, creating a powerful "tax stack" when combined with federal OBBBA expensing:
| State | Primary Economic Development Programs | Specialized MedTech Subsidies | Combined Incentive Impact |
|---|---|---|---|
| North Carolina | Job Development Investment Grant (JDIG), One North Carolina Fund | Cleanroom construction tax credits, custom community college training grants | Offsets 20–30% of initial CapEx build |
| Texas | Texas Enterprise Fund (TEF), Chapter 312 property tax abatements | Sales tax exemption on manufacturing machinery and cleanroom utilities | Eliminates state property taxes for up to 10 years |
| Indiana | Economic Development for a Growing Economy (EDGE) Tax Credit | Life sciences R&D tax credits, site preparation infrastructure grants | Offsets up to 15% of annual payroll taxes |
| Ohio | Job Creation Tax Credit (JCTC), JobsOhio R&D Center Grant | Dedicated MedTech commercialization capital grants | Direct cash grants for automated equipment installation |
Quality System Transfer & 510(k) Modification Rules for Onshoring
Transitioning device manufacturing from an offshore facility to a domestic U.S. plant requires strict adherence to FDA Quality System Regulation (QSR) / QMSR (ISO 13485:2016) requirements:
1. Process Validation (IQ / OQ / PQ) under 21 CFR 820.75
When setting up automated manufacturing lines at a new U.S. facility, manufacturers must re-validate all automated processes:
- Installation Qualification (IQ): Verifying that equipment is installed according to manufacturer specifications.
- Operational Qualification (OQ): Testing operational limits, thermal sealing parameters, and automated vision inspection thresholds.
- Performance Qualification (PQ): Executing consecutive commercial-scale production runs to prove process repeatability.
2. 510(k) Modification Triggers (21 CFR 807.81(a)(3))
Transferring manufacturing location does not automatically require a new 510(k), but manufacturers must evaluate whether facility changes affect device safety or effectiveness:
- No New 510(k) Required: If the manufacturing transfer uses identical materials, validated equivalent equipment, and unchanged product specifications, document the change in internal Design History Files (DHF) under Special Controls.
- New 510(k) Required: If relocating manufacturing requires material substitutions (e.g., sourcing domestic polymers) or process changes that alter biocompatibility or sterilization parameters, submit a new 510(k) prior to commercial distribution.
Buy American Act (BAA) and Build America, Buy America (BABA)
Federal procurement policies enforce preference for U.S.-manufactured end products through specific statutory content rules.
Buy American Act Thresholds (FAR Subpart 25.1)
The Buy American Act of 1933 (41 U.S.C. §§ 8301–8305), implemented via FAR Part 25, applies to direct federal agency purchases (such as VA hospital supplies and DoD medical kits).
| Calendar Period | Statutory BAA Domestic Content Threshold | Regulatory Reference |
|---|---|---|
| Pre-2022 | 55% Domestic Component Cost | Historical FAR 25.101 |
| 2022 – 2023 | 60% Domestic Component Cost | Federal Register Doc 2022-04173 |
| 2024 – 2028 (Current) | 65% Domestic Component Cost | FAR 25.101(a)(2)(i) |
| 2029 Onward | 75% Domestic Component Cost | FAR 25.101(a)(2)(ii) |
For a medical device to qualify as a U.S. Domestic End Product under BAA:
- The device must be manufactured in the United States; and
- The cost of domestic components must exceed 65% of the total component cost (for procurements in 2024–2028).
[!IMPORTANT] Price Evaluation Preference: BAA does not ban foreign offers; instead, it applies an evaluation penalty to foreign bids. When a federal agency evaluates competitive bids, it adds 20% to the price of a foreign offer (or 30% if the low domestic offer is a small business). If the domestic bid remains lower after applying the penalty, the contract is awarded to the domestic supplier.
Standard Federal Contract Clauses (FAR Flow-Downs)
Device suppliers bidding on federal agency solicitations must understand the exact FAR contract clauses incorporated into procurement solicitations:
- FAR 52.225-1 (Buy American — Supplies): Requires contractors to certify that each end product delivered under the contract qualifies as a domestic end product.
- FAR 52.225-5 (Trade Agreements): Applied when contract value exceeds TAA thresholds; permits delivery of only U.S.-made or TAA-designated country end products.
- FAR 52.225-6 (Trade Agreements Certificate): Formal compliance certification executed by the offeror detailing the exact country of origin for each offered line item.
The Trade Agreements Act (TAA) Exemption Framework
A common area of confusion among international medical device suppliers is why foreign-assembled devices frequently win VA and DoD contracts despite BAA requirements. The answer lies in the Trade Agreements Act of 1979 (TAA) (19 U.S.C. §§ 2501–2581).
How TAA Overrides BAA
Under FAR Subpart 25.4, for federal procurement contracts above specific monetary thresholds (typically $174,000 for supply contracts), the U.S. waives BAA requirements for products originating from TAA-Designated Countries.
- Contract Value Exceeds TAA Threshold ($174,000+):
- Check if device originates in a TAA Designated Country (EU, Japan, Mexico, South Korea, UK, Canada).
- Yes: Full TAA Compliance. The device is treated on par with U.S. domestic products. No BAA 20–30% price penalty applies.
- No (China, India, Vietnam): The device is disqualified from federal procurement unless an explicit agency waiver is granted.
- Check if device originates in a TAA Designated Country (EU, Japan, Mexico, South Korea, UK, Canada).
- Contract Value Below TAA Threshold (<$174,000):
- Buy American Act rules apply directly.
- Domestic Content ≥ 65%: Qualifies as U.S. Domestic End Product.
- Domestic Content < 65%: Foreign offer incurs a 20% to 30% price evaluation penalty.
- Buy American Act rules apply directly.
TAA-Designated Country Classification
| Category | Designated Countries / Regions | Federal Procurement Status |
|---|---|---|
| WTO GPA Partners | EU Member States, Japan, South Korea, United Kingdom, Canada, Taiwan, Australia, Israel | Fully Eligible: Treated equally with U.S. domestic products under TAA. |
| FTA Partners | Mexico, Singapore, Chile, Colombia, Costa Rica, Dominican Republic, Panama | Fully Eligible: Subject to specific procurement thresholds. |
| Non-TAA Countries | China, India, Malaysia, Thailand, Vietnam, Brazil | Ineligible / Restricted: Banned from TAA procurements unless explicit waiver granted. |
[!CAUTION] Substantial Transformation Standard: To claim origin in a TAA country (e.g., assembling components in Mexico), the device must undergo substantial transformation in that country, resulting in a new article of commerce with a new name, character, and use. Simple packaging, sterilization, or minor labeling in a TAA country does not confer origin.
Executive Order 13944 Essential Device Categories
Under Executive Order 13944, the FDA published a targeted list of 96 essential medical device product codes. Key device categories subject to federal procurement preference include:
| Clinical Product Category | Example Device Types | Key FDA Product Codes | Procurement Preference Scope |
|---|---|---|---|
| Respiratory & Anesthesia | Critical care ventilators, oxygen concentrators, CPAP devices, endotracheal tubes | CBH, BZD, NHO, CAF | Priority VA & DoD SNS procurement |
| Personal Protective Equipment (PPE) | N95 respirators, surgical gowns, nitrile gloves, face shields | MSH, FYA, LZA, OZA | BAA 65% content mandate |
| In Vitro Diagnostics & Reagents | Viral transport media, PCR testing kits, swab collection devices, extraction reagents | QJR, LLS, OOI | Federal stockpiling contracts |
| Infusion & Vascular Access | Smart infusion pumps, IV sets, central venous catheters, syringe pumps | FRN, FPA, LKB | Defense Logistics Agency (DLA) preferred |
| Patient Monitoring & Hardware | Pulse oximeters, multiparameter monitors, ECG leads, defibrillators | DQA, MHX, DSI | VA National Contract preference |
Regulatory & Customs Enforcement Failure Cases
Failure to properly classify manufacturing origin or miscalculating domestic content rules leads to severe legal penalties under U.S. law. The following composites illustrate the recurring enforcement patterns (dollar figures are illustrative):
Case 1: CBP Seizure for Country-of-Origin Misrepresentation
- Scenario: A diagnostic disposable company imported blood sampling cartridges manufactured in China, but routed shipments through Mexico for final outer packaging and labeling, claiming Mexican (TAA) origin.
- Outcome: U.S. Customs and Border Protection (CBP) issued a formal ruling finding that simple packaging did not satisfy the substantial transformation standard. The shipment was seized under 19 U.S.C. § 1304, and the importer was fined $1.2 million for false country-of-origin markings.
Case 2: False Claims Act Settlement for Non-TAA VA Sales
- Scenario: A durable medical equipment manufacturer sold hospital beds containing electronic control units produced in non-TAA countries to the Department of Veterans Affairs under a Federal Supply Schedule (FSS) contract.
- Outcome: The Department of Justice initiated a False Claims Act (31 U.S.C. § 3729) investigation based on false certifications under FAR 52.225-6. The manufacturer agreed to a $4.8 million civil settlement to resolve allegations of selling non-TAA compliant items to federal hospitals.
Onshoring ROI & Quantified Financial Modeling Example
When evaluating domestic reshoring versus offshore contract manufacturing, regulatory and operational leads should utilize a comprehensive cost-benefit model.
Quantified Case Example: $20M Capital Investment Evaluation
The following illustrative model shows how a medical device company might evaluate a $20 million automated assembly line for diagnostic disposable cartridges. Figures are directional planning estimates, not a quote; verify all tax, tariff, and labor inputs against current schedules before deciding.
Financial Comparison: U.S. Onshoring vs. Mexico Nearshoring vs. China Manufacturing
──────────────────────────────────────────────────────────────────────────────────
Factor U.S. Factory (NC) Mexico Plant (TAA) China Plant
──────────────────────────────────────────────────────────────────────────────────
Initial CapEx Investment $20,000,000 $16,000,000 $12,000,000
Y1 OBBBA Tax Savings (35% Tax) -$7,000,000 -$1,120,000 -$840,000
BAA Price Preference Penalty 0% 0% (TAA Exempt) +20% to 30%
Section 232 Tariff Risk 0% Tariffs Low Risk High Tariff Risk
Annual Labor Cost Premium +$2,500,000 +$600,000 Base ($0)
Shipping & Logistics Lead Time 2 Days 5 Days 28 Days
──────────────────────────────────────────────────────────────────────────────────
Net 5-Year Present Value (NPV) +$14,200,000 +$11,800,000 +$6,400,000
──────────────────────────────────────────────────────────────────────────────────
Comparative Incentive Matrix by Manufacturing Location
| Strategy Factor | Domestic U.S. Production | TAA Partner (e.g., Mexico) | Non-TAA (e.g., China) |
|---|---|---|---|
| Buy American Act Status | 100% Compliant (0% Penalty) | Exempt via TAA (0% Penalty) | Non-Compliant (+20-30% Penalty) |
| Federal Grant Eligibility | High (DPA Title III, BARDA) | Moderate (Cross-border grants) | Ineligible |
| Section 232 Tariff Risk | Zero Risk | Low Risk | High Risk (Subject to tariffs) |
| Tax Expensing (OBBBA) | 100% Y1 Expensing | Standard Amortization | Standard Amortization |
| Labor & Overhead Cost | High ($25–$45/hr) | Moderate ($5–$12/hr) | Low ($4–$8/hr) |
| Supply Chain Transit Time | 1–3 Days | 3–7 Days (Trucking) | 20–35 Days (Ocean Freight) |
For strategies on executing reshoring decisions, consult our Medical Device Manufacturing Reshoring & Nearshoring Strategy Guide, and evaluate tariff exposure via our Medical Device Tariffs & Trade Policy Guide.
Step-by-Step Playbook for Accessing Federal Manufacturing Incentives
- Conduct a Product Code Audit: Map your device portfolio against the 96 product codes in EO 13944 and BAA federal procurement lists.
- File an Expression of Interest via the DoD IBAS Portal: For high-priority devices, submit facility expansion plans to the Office of Industrial Base Policy under DPA Title III open announcements.
- Verify Country-of-Origin Substantial Transformation: If manufacturing in nearshore locations like Mexico, ensure assembly steps satisfy the substantial transformation test to secure TAA eligibility.
- Structure CapEx under OBBBA Section 168(n): Work with corporate tax counsel to classify cleanroom construction and automated manufacturing machinery as Qualified Production Property for immediate Y1 write-offs.
- Mitigate Supply Chain Exposure: Audit tier-1 and tier-2 component suppliers for non-TAA dependencies to ensure BAA domestic content thresholds (65%) are preserved. Refer to our Medical Device Supply Chain Risk Management Guide.
Frequently Asked Questions (FAQs)
Is there a device-specific "Made in America" Executive Order in 2026?
While 2025 Executive Orders focused heavily on active pharmaceutical ingredients (APIs), medical devices remain governed by Executive Order 13944 (issued August 2020), which covers 96 medical device product codes, alongside procurement provisions under the Buy American Act and BABA.
What is the current Buy American Act domestic content threshold for medical devices?
For calendar years 2024 through 2028, the BAA domestic content requirement is 65%. It will automatically increase to 75% in calendar year 2029. Offerors selling to federal agencies must certify component costs against these statutory limits.
Can devices manufactured in China be sold to the VA or DoD?
Generally, no. China is a non-TAA country. For federal procurements above the TAA threshold ($174,000), products originating in China are banned unless the contracting officer secures a formal agency waiver proving domestic or TAA-compliant items are unavailable.